 |
|
|
| |
Week 96 Weight and Lipid Changes From Baseline Among Participants Receiving Cabotegravir + Rilpivirine Long-Acting or Comparator Therapy in the ATLAS-2M and FLAIR Studies
|
| |
| |
AIDS 2022 July 29 - Aug 1 Montreal
Parul Patel1, Emilie R. Elliot2, Ronald D'Amico1, Louise Garside3, Conor Smith4, Jeremy Roberts5, Joseph W. Polli1, Rodica Van Solingen-Ristea6, Chloe Orkin7, Edgar T. Overton8, Susan Swindells9, Bryan Baugh10, Jean van Wyk2
1ViiV Healthcare, Research Triangle Park, NC, United States; 2ViiV Healthcare, Brentford, United Kingdom; 3Phastar, Macclesfield, United Kingdom; 4Parexel International, Sheffield, United Kingdom;
5GlaxoSmithKline, Mississauga, ON, Canada; 6Janssen Research & Development, Beerse, Belgium; 7SHARE Collaborative, Department of Immunobiology, Queen Mary University, London, United Kingdom;
8University of Alabama at Birmingham, Birmingham, AL, United States; 9University of Nebraska Medical Center, Omaha, NE, United States; 10Janssen Research & Development, Titusville, NJ, United States
|
| |
|
|
|
|
|
